TABLE 4.
Treatment‐related TEAEs occurring in >1 patient treated with LAN
| Treatment‐related TEAEs | Total (n = 50) |
|---|---|
| Gastrointestinal | |
| Abdominal pain | 5 (10.0) |
| Diarrhoea | 5 (10.0) |
| Vomiting | 3 (6.0) |
| Steatorrhoea | 2 (4.0) |
| Upper abdominal pain | 2 (4.0) |
| Flatulence | 2 (4.0) |
| Nausea | 2 (4.0) |
| General disorders and administration site conditions | |
| Injection site mass | 5 (10.0) |
| Injection site pain | 2 (4.0) |
| Metabolism and nutrition disorders | |
| Decreased appetite | 2 (4.0) |
| Nervous system disorders | |
| Dizziness | 2 (4.0) |
Abbreviations: LAN, lanreotide autogel; TEAE, treatment‐emergent adverse event.